Table 3.
Association of psoriasis with sarcopenia or myosteatosis by logistic regression analysis in the study population after propensity score matching.
| OR | 95% CI | p-value | |
|---|---|---|---|
| Sarcopenia | |||
| Psoriasis (unadjusted) | 0.63 | 0.34–1.20 | 0.161 |
| Psoriasis (adjusted Model 1) | 0.60 | 0.32–1.16 | 0.128 |
| Psoriasis (adjusted Model 2) | 0.51 | 0.25–1.19 | 0.136 |
| SMD-defined myosteatosis | |||
| Psoriasis (unadjusted) | 2.93 | 1.91–4.49 | <0.001 |
| Psoriasis (adjusted Model 1) | 3.71 | 2.25–6.11 | <0.001 |
| Psoriasis (adjusted Model 2) | 3.16 | 1.86–5.37 | <0.001 |
| IMAT%-defined myosteatosis | |||
| Psoriasis (unadjusted) | 1.88 | 1.19–2.97 | 0.007 |
| Psoriasis (adjusted Model 1) | 2.00 | 1.21–3.28 | 0.006 |
| Psoriasis (adjusted Model 2) | 1.76 | 1.04–3.00 | 0.037 |
BMI, body mass index; CI, confidence interval; IMAT%, percentage of intermuscular adiposity tissue; OR, odds ratio; SMD, skeletal muscle radiodensity.
Model 1: adjusted for age, sex, and BMI.
Model 2: further adjusted for smoking, diabetes, fatty liver, albumin, total cholesterol, high-density lipoprotein-cholesterol, and low-density lipoprotein-cholesterol based on Model 1.